Aridis Pharmaceuticals Stock Forecast, Price & News

Aridis Pharmaceuticals (NASDAQ:ARDS) Frequently Asked Questions

Is Aridis Pharmaceuticals a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aridis Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Aridis Pharmaceuticals stock.
View analyst ratings for Aridis Pharmaceuticals or view top-rated stocks.

How has Aridis Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Aridis Pharmaceuticals' stock was trading at $6.46 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ARDS shares have decreased by 63.0% and is now trading at $2.39.
View which stocks have been most impacted by COVID-19.

Are investors shorting Aridis Pharmaceuticals?

Aridis Pharmaceuticals saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 5,100 shares, a drop of 67.1% from the October 31st total of 15,500 shares. Based on an average trading volume of 33,300 shares, the short-interest ratio is presently 0.2 days. Approximately 0.1% of the company's stock are short sold.
View Aridis Pharmaceuticals' Short Interest.

When is Aridis Pharmaceuticals' next earnings date?

Aridis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 29th 2022.
View our earnings forecast for Aridis Pharmaceuticals.

How were Aridis Pharmaceuticals' earnings last quarter?

Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($1.94) EPS for the quarter, missing the Zacks' consensus estimate of ($0.51) by $1.43. The firm earned $0.52 million during the quarter.
View Aridis Pharmaceuticals' earnings history.

What price target have analysts set for ARDS?

3 brokers have issued 12-month price targets for Aridis Pharmaceuticals' shares. Their forecasts range from $10.00 to $19.00. On average, they anticipate Aridis Pharmaceuticals' share price to reach $15.67 in the next twelve months. This suggests a possible upside of 555.5% from the stock's current price.
View analysts' price targets for Aridis Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Aridis Pharmaceuticals' key executives?

Aridis Pharmaceuticals' management team includes the following people:

• Vu L. Truong, Director, Chief Executive & Scientific Officer (LinkedIn Profile)
• Fred Kurland, Chief Financial & Accounting Officer
• Hasan Jafri, Chief Medical Officer
• Steven M. Chamow, Vice President-Research & Development
• Lisa Sher, Head-Investor & Public Relations

Who are some of Aridis Pharmaceuticals' key competitors?

Some companies that are related to Aridis Pharmaceuticals include Tyme Technologies (TYME), Puma Biotechnology (PBYI), IMV (IMV), Savara (SVRA), Kazia Therapeutics (KZIA), scPharmaceuticals (SCPH), Palatin Technologies (PTN), Mereo BioPharma Group (MREO), Tiziana Life Sciences (TLSA), ProMetic Life Sciences (PFSCF), NervGen Pharma (NGENF), Gemini Therapeutics (GMTX), Concert Pharmaceuticals (CNCE), Entasis Therapeutics (ETTX) and BioLineRx (BLRX).
View all of ARDS's competitors.

What other stocks do shareholders of Aridis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aridis Pharmaceuticals investors own include Juno Therapeutics (JUNO), VBI Vaccines (VBIV), Cidara Therapeutics (CDTX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Matinas BioPharma (MTNB), Gilead Sciences (GILD), Ocular Therapeutix (OCUL), Pluristem Therapeutics (PSTI) and SCYNEXIS (SCYX).

When did Aridis Pharmaceuticals IPO?

(ARDS) raised $28 million in an IPO on Tuesday, August 14th 2018. The company issued 2,000,000 shares at $13.00-$15.00 per share. Cantor acted as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers.

What is Aridis Pharmaceuticals' stock symbol?

Aridis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARDS."

Who are Aridis Pharmaceuticals' major shareholders?

Aridis Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include AIGH Capital Management LLC (1.24%), Millennium Management LLC (0.62%), BlackRock Inc. (0.35%), Geode Capital Management LLC (0.30%) and Wealth Architects LLC (0.12%). Company insiders that own Aridis Pharmaceuticals stock include John F Hamilton and Vu Truong.
View institutional ownership trends for Aridis Pharmaceuticals.

Which major investors are selling Aridis Pharmaceuticals stock?

ARDS stock was sold by a variety of institutional investors in the last quarter, including AIGH Capital Management LLC.
View insider buying and selling activity for Aridis Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Aridis Pharmaceuticals stock?

ARDS stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Geode Capital Management LLC, Wealth Architects LLC, and BlackRock Inc.. Company insiders that have bought Aridis Pharmaceuticals stock in the last two years include John F Hamilton, and Vu Truong.
View insider buying and selling activity for Aridis Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Aridis Pharmaceuticals?

Shares of ARDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aridis Pharmaceuticals' stock price today?

One share of ARDS stock can currently be purchased for approximately $2.39.

How much money does Aridis Pharmaceuticals make?

Aridis Pharmaceuticals has a market capitalization of $33.59 million and generates $1 million in revenue each year. The company earns $-22.33 million in net income (profit) each year or ($3.79) on an earnings per share basis.

How many employees does Aridis Pharmaceuticals have?

Aridis Pharmaceuticals employs 33 workers across the globe.

What is Aridis Pharmaceuticals' official website?

The official website for Aridis Pharmaceuticals is www.aridispharma.com.

Where are Aridis Pharmaceuticals' headquarters?

Aridis Pharmaceuticals is headquartered at 5941 Optical Ct, San Jose CA, 95138.

How can I contact Aridis Pharmaceuticals?

Aridis Pharmaceuticals' mailing address is 5941 Optical Ct, San Jose CA, 95138. The company can be reached via phone at (408) 385-1742, via email at [email protected], or via fax at 408-960-3822.